

Interim report

January 1 – March 31, 2026

The first quarter in figures

- Net sales were TSEK 14,278 (8,856), +61%, cleared for currency effects +80%.
- The loss after tax was TSEK 24,490 (20,682).
- The loss per share was SEK 0.03 (0.07).
- The cash flow from current operations was negative in the amount of TSEK 26,573 (26,001).
- The gross margin was 49.2% (70.5%).
- Electrode sales volume increased by 70% and was 30,460 (17,870) units. Repeat sales of electrodes to existing customers increased by 73% (incl deliveries to Castle).

Important events during the quarter

- Overall sales increased by 61% (+80%, before currency effects). Sales in Germany within the skin cancer segment were at the same level as Q1-25 (increased by 5% in local currency). **Sales in the US skin cancer market increased by 79% (109% in local currency)** while the sales within the skin barrier segment increased by 1,042%.
- The gross margin was negatively affected in the quarter by the currency development (negative impact of over 5%), **continued deliveries of products to Castle Biosciences for clinical studies**, increased price on gold and continued investments to ramp up production.

- SciBase announced the outcome of the offer to repurchase outstanding warrants of series TO 2. In total, 83.9% of the TO2 holders accepted the offer.
- SciBase announced the outcome of the performed rights issue, where the issue was subscribed to 96.4% and provides the company with approximately SEK 80 million before issue costs.
- A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns.
- Dr Hess, a US physician at Center City Dermatology in Philadelphia, published a clinical article describing his real-world experience with Nevisense in improving melanoma detection.
- A recalculation of the terms for the remaining TO 2 warrants has been carried out after the completion of the rights issue.
- Nevisense (EIS) included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma.
- SciBase receives approval from the FDA for extended labelling in the US.


Important events after the end of the period

- SciBase reaches milestone with over 400,000 tests sold globally.
- SciBase published the notice to attend the 2026 AGM.
- SciBase published the annual report for 2025.

Financial overview

THE GROUP	Apr 1, 2025 -			
	Jan 1 - Mar 31 2026	Mar 31, 2026 2025	Rolling-12 2025	Jan 1 - Dec 31 2025
Net sales, SEK ths	14 278	8 856	45 883	40 461
Gross margin, %	49,2%	70,5%	60,8%	67,0%
Equity/Asset ratio, %	56,0%	71,6%	61,8%	12,8%
Net indebtedness, multiple	0,78	0,40	0,62	6,84
Cash equivalents, SEK ths	71 255	34 295	71 255	22 604
Cashflow from operating activities, SEK ths	-26 573	-26 001	-85 150	-84 579
Earnings per share (before and after dilution), SEK	-0,03	-0,07	-0,19	-0,24
Shareholder's equity per share, SEK	0,07	0,14	0,10	0,02
Average number of shares, 000'	819 748	298 710	490 616	360 357
Number of shares at closing of period, 000'	1 022 530	338 296	1 022 530	414 183
Share price at end of period, SEK	0,35	0,42	0,35	0,29
Number of sold electrodes, pieces	30 460	17 870	98 770	86 180
Average number of employees	46	35	33	37

Definitions and a glossary are provided on page 18,



Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma

Nevisense (EIS) is included in the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for melanoma. The guidelines refer to EIS as a diagnostic support technology to aid in the detection of melanoma.



Comment by CEO Pia Renaudin

“ Expanded collaboration with Castle Biosciences and new strategy in the US delivers strong growth”


Highlights Q1 2026

- New record-breaking quarter with sales in Q1 increasing by 61% and adjusted for currency effects by 80%.
- Sustained US momentum with sales increasing by 79%, 109% in local currency.
- Germany shows continued growth, +5% in local currency.
- The SciBase and Castle collaboration continues according to plan.
- Accumulated more than 400,000 tests sold.

US shows good growth

We have continued to achieve success primarily in the US market, but we generally see a great deal of interest in Nevisense in the markets we operate in. During the first quarter, we passed an important milestone with more than 400,000 tests sold, which is proof of the value Nevisense represents for our patients. The largest base of electrodes sold is in Germany, but in recent quarters we have seen accelerating growth in the US: Total sales amounted to SEK 14.3 (8.9) million, driven by increasing growth in the US. During the quarter, deliveries of electrodes and Nevisense Go to Castle continued for the planned joint studies. Adjusted for sales to Castle and currency effects, the underlying growth in the quarter amounted to 37%.

In the US, sales increased by a total of 79%, which corresponds to growth of 109% in local currency. After a strong fourth quarter in Germany, we saw slightly lower growth in the first quarter of 2026 of 5%.



Percentage quarterly sales growth compared to the same quarter in the previous year.

The collaboration with Castle Biosciences continues according to plan

During the first quarter, we have continued our deliveries to Castle based on the order we received in the latter part of 2025, and I expect the first joint study to start in the second quarter. The study focuses on developing a test to predict flare-ups in patients

with atopic dermatitis (AD), a large and underserved market characterized by unpredictable disease activity. The study will use Nevisense Go in a home-use setting, enabling longitudinal monitoring of skin barrier function and supporting the development of a clinically actionable tool for proactive disease management.

Submission of first reimbursement coverage to private insurance Company

We have started the year strongly in the US market, with extended labelling received from the FDA and Nevisense being included in the NCCN (National Comprehensive Cancer Network) US guidelines for melanoma. Our offering of being able to give healthcare professionals better conditions to increase diagnostic accuracy and detect skin cancer early is starting to have a good impact. During the quarter, we submitted our first application for reimbursement to a leading private insurance company. We have now come so far in our work of obtaining broader reimbursement that we have hired our own payer access specialist. I also expect that during the year we will be able to obtain reimbursement from several payers. Total sales in the US amounted to SEK 4.9 (2.7) million for the first quarter, which corresponds to growth of 79%, in local currency an increase of 109%.

Additionally, an article highlighting a U.S. physician’s practical experience with Nevisense was published in The Dermatologist, a leading U.S. clinical dermatology publication. In the article, Dr. Stephen D. Hess, MD, PhD, FAAD, highlights his practical experience integrating Nevisense into routine melanoma detection. In the article, Dr. Hess describes how Nevisense provides objective data to complement visual examination and dermoscopy in the evaluation of atypical pigmented lesions, and that Nevisense adds objective risk stratification in cases that are clinically challenging. According to Dr. Hess, Nevisense provides objective information from below the skin surface in real time, which improves clinical judgment and supports more accurate biopsy decisions. The article has already led to increased interest and several new customers.

Interest in Germany for new applications

We see continued strong interest in Germany for Nevisense V, although the growth rate in the first quarter, after a strong fourth quarter, has slowed down somewhat. Total sales amounted to SEK 5.8 (5.8) million, which in local currency corresponds to a growth of 5%. We have now started our own clinical study in Germany linked to atopic dermatitis to meet the interest in applying Nevisense in the barrier area and thereby broaden the use and benefit for patients.

During the quarter, we included the first patient in the study.

Investments and increased costs weigh on the gross margin

The gross margin in the first quarter continued to be impacted by our ongoing investments in capacity to meet future demand, continued deliveries of products to Castle (for a clinical study with very low margins) and increased costs for certain components such as gold. For the first quarter, the gross margin was 49.2% (70.5). Adjusted for deliveries to Castle during the quarter and currency effects, the gross margin was 67.1%.

Given the cost increases we are seeing on certain components, we have also initiated a review of our suppliers and cost structure and have already taken action. I believe that we will see the effects of the measures we implemented this quarter as early as the second half of the year. As capacity utilization improves and we see an impact on the cost side from our actions, I expect a return to previous gross margin levels.

Strengthened financial position

In January, the previously announced rights issue was completed. It was subscribed to 96.4 percent and SciBase was provided with approximately SEK 79.9 million before issue costs. The strengthened financial position allows us to fully focus on delivering on our strategy and our collaboration with Castle.

I am very grateful for the support we have among our existing owners, which gives us the opportunity to further advance our positions.

Platform in-place for continued growth

Over the past year we have come a long way in expanding patients' access to improved skin cancer diagnostics. Together with Castle we are also well positioned to accelerate studies and opportunities in the barrier area. Much work remains to be done in all

areas and in our markets, but the first quarter results confirm we are on the right track.

I expect continued strong growth and an improved gross margin as our measures take effect. I am proud of the team's work to expand patient access to better diagnostics and grateful for the support we have from our owners, which enables us to continue to develop SciBase together.



*Pia Renaudin, CEO
Sundbyberg May 7th, 2026*

SciBase in brief

SciBase – Vision to Value Creation

Vision

Pioneering prediction and prevention in dermatology.

Mission

Products: To develop unique, point-of-care platforms that combine AI (artificial intelligence) with our advanced EIS (electrical impedance spectroscopy).

Providers: To empower healthcare professionals to improve diagnostic accuracy, enable disease monitoring, and facilitate early intervention of skin cancer and skin disorders.

Patients: Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection, and reducing overall healthcare costs.

Value creation

To become the global leader in non-invasive, high-precision skin assessment for cancer detection and skin barrier evaluation, capturing a significant share of a \$1 billion.

The company has been listed on Nasdaq First North Growth Market exchange since June 2, 2015.

For more information, please visit www.scibase.com

Business model

The company's business model is based on customers initially purchasing a Nevisense platform and consumables (electrodes).

Short facts

- Skin cancer is the most common and fastest-growing form of cancer in the world.
- Melanoma is the most dangerous form of skin cancer with a high mortality rate if not detected early.
- More than 5 million cases of skin cancer detected annually in the US.
- An estimated 234,680 cases of melanoma will be diagnosed in the U.S. in 2026.
- In 2022 skin cancer caused 128,000 deaths.
- SciBase addressable market, in skin cancer alone, is estimate to SEK 4 billion.
- The Nevisense® platform provides physicians with an objective instrument to support better diagnoses.

Certified Advisor (CA)

DNB Carnegie Investment Bank AB (publ)





Phone: +46 (0)73 856 42 65

E-mail: certifiedadviser@carnegie.se

"In everyday practice, many pigmented lesions fall into a diagnostic gray zone," said Dr. Hess. "Nevisense adds objective, real-time information beneath the skin's surface, enhancing clinical judgment and supporting more accurate biopsy decisions". Stephen D. Hess, MD, PhD, FAAD, has published a clinical article highlighting his real-world experience integrating Nevisense into routine melanoma detection. The article was published in The Dermatologist, a leading U.S. clinical dermatology journal.

Skin barrier – a hot topic

- Atopic dermatitis (eczema) is the most common chronic disease with over 200 million patients in the US and Europe and affects about 20% of infants and 7% of adults.
- Skin barrier related diseases such as food allergy and atopic dermatitis (eczema), are a growing problem and there is a large global unmet need for tools for prediction, measurement and management. The market for atopic dermatitis is expected to grow at ~10% annually until 2030.
- Impaired skin barrier is growing with long-term trends such as climate change, increased air pollution, change and loss of biodiversity



The First quarter

Net Sales

Net sales for the first quarter of 2026 reached a new record high with sales of TSEK 14,278 (8,856), an increase of 61%. Cleared for currency effects sales increased by 80%. The increased sales are mainly due to increased US (+79% - +109% in local currency) sales, continued delivery of products to Castle Biosciences for the first clinical study (approximately MSEK 3 delivered of the total order value of around MSEK 8 – accumulated around 50% of the total order delivered). Excluding Castle sales increased by 25% and 37% when cleared for currency effects. Given the nature of research projects sales within the barrier segment continue to vary between quarters, in the period sales (excluding sales to Castle) decreased by 6%.

Sales of devices were TSEK 3,632 (893) and sales of electrodes amounted to TSEK 10,646 (7,963) corresponding to about 90% of the turnover reflecting the Company’s business model. The total sales within the new skin barrier application were TSEK 3,473 (228) in the period.

Sales in Germany in the skin cancer area accounted for 54 (66)% of the sales in the period and were at the same level as Q1 2025. In local currency the sales in Germany increased by 5%.

Sales in the US skin cancer segment accounted for 45 (31)% of the sales in the period and increased by 79% (109% in local currency). During this period, a number of new US customers have been obtained at the same time as existing customers continue to buy electrodes.

Electrode sales in the quarter reached 30,460 (17,870) sold, an increase of 70%. After a strong end of 2025 electrodes sales in volume decreased by 3% in

Germany, US electrode volumes grew by 99% while barrier volumes increased by 1,727%. Total repeat sales of electrodes increased by 73%.

Operating profit/loss

The operating loss for the period January - March 2026 was TSEK 24,453 (19,578), an increased loss of TSEK 4,875. The increased sales contributed to an improvement in earnings, which was balanced by increased sales and marketing expenses through increased investments in the US, increased investments in resources for production capacity and automation and a lower gross margin. SciBase organization in the US was established during the second half of 2024 and has further strengthened in the period including dedicated resources for reimbursement. The total operating expenses increased in the period by TSEK 5,657 (22%) and is primarily driven by increased US investments. The operating income was positively affected by currency effects with around MSEK 0.8. The current trend with a strengthening SEK vs mainly the USD will have a positive impact on the operating income as SciBase currently has higher operating expenses than sales in USD – compared to the average currency rate in Q1-25 the SEK has strengthened with around 15%.

The gross margin in the period was 49.2 (70.5%). Negative currency effects (over 5%), continued deliveries of products to Castle Biosciences for clinical studies (at a very low margin), higher price on gold compared to Q1-25 and continued resource build-up to increase production capacity, which initially affects the yield, have all contributed to the lower margin in the period. SciBase focuses on the margin and the cost for

the electrode and in the quarter the margin for the electrode was close to 65 (76)% (lower than usual due to deliveries to Castle – cleared for Castle the margin was 71 %) while the margin for device sales was around 4 % - cleared for Castle deliveries it was 15% in the period. When cleared of currency effects the overall gross margin would be closer to 54.6%. If the margin is also adjusted for deliveries to Castle, the margin would have been closer to 67%. The overall margin remains very dependent on electrode production and sales volumes and will vary between quarters.

Sales and marketing expenses increased by TSEK 4,717 and were TSEK 20,817 (16,101). The expenses have increased primarily due to increased US resources and activities focused on reimbursement in the US. In the period the US organization was further expanded including dedicated resources for reimbursement. During the period, the first formal application for reimbursement was submitted to a major private insurance company.

Administration expenses for the period were TSEK 4,105 (3,459), an increase of TSEK 646. The increase is primarily attributable to the in Q1-26 performed capital raise and QA activities.

Development expenses for the period were TSEK 6,280 (5,850), an increase of TSEK 429. The development expenses are mainly driven by increased investments in production ramp-up and ongoing projects within product development which require increased resources to run.

The financial costs/income have affected the results negatively in the period with MSEK 0.0 (negatively MSEK 1.1). In Q4-25, the Group's accounting for the loan to the American subsidiary SciBase Inc. changed. The loan is treated as part of the net investment in foreign operations in accordance with IAS 21. This means that exchange rate differences that arise when translating the receivable are reported in other comprehensive income instead of in the income statement. The change has been applied retroactively, and comparative figures have been restated.

The effect for Q1-25 means an improved result for the period but a corresponding change in other

comprehensive income. The comprehensive income for the period is unchanged. The effect for all reported periods is shown in the table below:

Amounts in KSEK	Q4 2025	Q4 2024
Profit/loss for the period before change	-24 073	-27 510
Effect of net investment classification	-417	6 829
Profit/loss for the period after change	-24 490	-20 681
Comprehensive Income before change	-743	6 581
Effect of net investment classification	417	-6 829
Comprehensive Income after change	-325	-248
Comprehensive Income for the period (unchanged)	-24 816	-20 929

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents were TSEK 22,604 and, at the end of the period, TSEK 71,255.

Cash flow from current operations for the period was negative to the amount of TSEK 26,573 (26,001), of which changes in working capital amounted to negative TSEK 3,244 (negative 5,590) which was mainly attributable to decreased short-term liabilities and increased receivables while in 2024 it was mainly due to decreased short-term liabilities. Total cash flow for the period was positive to the amount of TSEK 48,988 (positive 23,110). During the period, the company carried out a rights issue which net, after issue costs, provided the company with approximately SEK 76.3 million. During Q1-25, two new issues were carried out, one directed and one rights issue, which net provided the company with approximately SEK 49.8 million.

Net investment in tangible assets for the period was TSEK 0 (0). Investments in intangible assets for the period were TSEK 0 (0).

Depreciation of tangible assets was charged against earnings for the period to the value of TSEK 993 (759) of which TSEK 704 (676) are due to leased assets.

Other disclosures

Shareholders

At the end of the period, SciBase Holding AB had approximately 2,677 shareholders. Per March 31, the five largest shareholders represented approximately 58.8% of the capital and votes. The total number of shares per March 31, 2026, was 1,022,530,000. The largest shareholders as per March 31, 2026, were Ribbskottet AB (21%), Castle Biosciences Inc (20%), Coeli Wealth Management (7%), Ejendal Industries AB (7%) and Hagagruppen AB (5%).

Market overview

SciBase is active within both skin cancer detection and skin barrier assessment. SciBase's Nevisense platform addresses multiple sizeable clinical application areas.

Skin cancer

Skin cancer is believed to be the most common form of cancer in the world. More than 5 million cases of skin cancer are reported every year in the US alone, which is more than all other cancers combined. SciBase estimate the total addressable market potential for SciBase to be around 400 million USD per year or approximately BSEK 3.7.

The population of non-melanoma skin cancer patients includes more than ten times the number of patients compared to the melanoma patient population. SciBase estimates that the potential for the use of Nevisense amounts to at least 4 million examinations or tests annually. Given this, non-melanoma skin cancer is estimated to have a total market potential of approximately SEK 1.4 billion annually.

Skin barrier

An exciting application area is skin barrier assessment. The skin barrier stops irritants, allergens etc. entering, and water from leaving the body. An impaired skin barrier at birth can be a predictor of the development of Atopic Dermatitis (AD) or eczema. The development of AD often precedes the development of other atopic diseases such as food allergies, allergic rhinitis and allergic asthma. The ability to easily detect an impaired skin barrier can help detect, manage and treat atopic diseases before the development of AD. There is a high interest from the research community and this group is the short-term sales target within the barrier area.

As many as up to 20% of all children and 7% of all adults suffers from atopic dermatitis. The application area includes disease development prediction in infants, diagnostic and therapy selection tests in a clinical setting, and regular tests in the home in order to monitor and manage the disease. The total number of measurements for all patients with atopic dermatitis could potentially exceed the tens of million per year.

Initially SciBase focuses on the launch of atopic dermatitis in Germany and sales towards researchers.

Employees

At the end of the period, the number of employees amounted to 49 [36], of whom 51 [50]% were women. This includes the production employees at our Uppsala production facility and sales representatives in Germany and the US.

Financing

The Board of Directors regularly reviews the Company's current and projected cash flows to ensure it has sufficient resources to operate the business and execute the strategic plan. The Company's long-term cash requirements depend largely on its ability to successfully commercialize Nevisense. This, in turn, is influenced by several factors, including costs associated with inclusion in insurance systems, reimbursement levels, marketing expenses, and compliance with regulatory requirements.

Based on the strategic plan, the Board determined at the end of 2025 that further capital was needed and initiated a rights issue, completed in January 2026, which raised approximately SEK 80 million before costs. The issue was subscribed to 96.4 percent, which the Board views as a strong vote of confidence from both existing and new shareholders. In addition, during 2025, the Company secured a SEK 20 million loan through its expanded partnership with Castle Biosciences.

With this capital injection, combined with revenue from the growing business, the Board believes the Company's capital will be sufficient through 2026. However, the Company remains in an expansion phase, with increasing sales but not yet generating positive cash flow. The Board therefore expects that additional financing will be required to support the strategic plan beyond 2026. As of March 31, 2026, the Group's cash and cash equivalents totaled SEK 71.3 million.

Given the strong commercial progress in 2025 and beginning of 2026, the strategic partnership with Castle Biosciences, a broadened shareholder base, and

continued capital market interest, the Board believes conditions for raising additional capital are favorable. However, as future capital raises are partly outside the Company's control, the Board notes that funding for the 12-month period following the issuance of the annual report is not fully secured. The Board is actively evaluating various financing options and is confident that the Company's long-term capital needs can be secured.

Transactions with related parties

During the year, the parent Company SciBase Holding AB invoiced TSEK 1,186 [1,186] to the fully owned subsidiary SciBase AB, which corresponds to a 100% of the parent Company's turnover in the period. During the reporting period there were no other transactions with related parties that had any material impact on the Group or Parent Company's position and earnings.

Risks and uncertainty

The principal risks and sources of uncertainty for SciBase include, albeit not exclusively, financial risks, such as the future earnings trend, financing, and currency and credit risks. In addition to market risks, there are also risks associated with SciBase's operations, such as obtaining necessary approval from authorities, product development, patents and intellectual property rights, product responsibility and forward-looking information. Nor are there any guarantees that the Company will be able to secure the financial resources necessary to conduct its operations. Further information on the Company's risk exposure can be found on pages 40-44 of SciBase's 2025 Annual Report.

Parent Company

SciBase Holding AB [publ], corporate identity number 556773-4768, is the Parent Company of the Group. The company was formed in 2009 following a restructuring of the Group. The actual operations are conducted by the fully owned subsidiary SciBase AB.

As per March 31, 2026, there were two employees, the CEO and the Groups finance department. The operations consist of consulting activities for the rest of the Group. The company's main task is of a financial nature – to fund the Group's operational activities.

Net sales for the period reached TSEK 1,186 [1,186]. The loss for the period amounted to TSEK 14,258 [17,845]. The Company's net sales consist of invoiced consultancy fees to the fully owned subsidiary SciBase AB.

The shareholders' contributions to the fully owned subsidiary SciBase AB are from 2016 and onwards charged to earnings and not booked as a financial tangible asset. The shareholders' contribution expensed during the period was MSEK 11.4 [15,6].

Significant events during the quarter

SciBase announced the outcome of the repurchase offer regarding all warrants of series TO 2 that the board of directors decided on November 7, 2025 (the "TO 2 Offer"). The outcome shows that holders of a total of 418,150,952 warrants of series TO 2 accepted the TO 2 Offer, where two (2) warrants of series TO 2 were entitled to one (1) newly issued share in the

Company. The outcome of the TO 2 Offer corresponds to approximately 83.9 percent of all outstanding warrants of series TO 2 and results in 209,075,476 new shares in SciBase being issued. After the completion of the TO 2 Offer, the number of outstanding warrants of series TO 2 amounts to 80,383,883.

SciBase announced the outcome of the rights issue of shares that the Company decided on December 29, 2025. The rights issue was subscribed to approximately 96.4 percent, of which approximately 61.3 percent was subscribed with the support of subscription rights and approximately 35.1 percent without the support of subscription rights. The Rights Issue thus provides the Company with approximately SEK 79.9 million before issue costs. The Rights Issue increases the number of shares by 399,271,881 and after the rights issue and TO2 offering, the total number of shares amounts to 1,022,530,000. The Rights Issue was carried out without customary underwriters.

A new study was presented in an oral presentation at the AAAAI conference in Philadelphia February 27 – March 2. The study from Icahn school of Medicine of Mount Sinai in New York was conducted on newborns who have a first-degree relative affected by atopic disease – meaning they had an increased risk of developing atopic dermatitis. The study included 19 infants, among whom Nevisense successfully identified those who later developed atopic dermatitis (AD). Within the first year of life, eight of the nineteen infants developed AD, and their Nevisense scores at birth were significantly higher. The conclusion from the study was “Higher EIS scores, suggestive of impaired skin barrier, within the first week of life were significantly associated with development of AD in the first year of life.

An article highlighting the practical experiences of an American physician with Nevisense was published in The Dermatologist, a leading American clinical dermatology publication. In the article DR Stephen D. Hess, MD, PhD, FAAD, highlights his practical experience integrating Nevisense into routine melanoma detection. In the article, Dr. Hess describes how Nevisense provides objective data to complement visual examination and dermoscopy in the evaluation of atypical pigmented lesions, and that Nevisense adds objective risk stratification in cases that are clinically challenging.

In accordance with the terms and conditions of the warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles to subscription and the subscription price shall be recalculated due to the rights issues that have been carried out. In light of this, SciBase Holding AB has carried out a recalculation of the warrants of series TO 2 due to the rights issue of shares that the Board of Directors decided on on December 29, 2025. After the recalculation, the Company announced that the number of shares that each warrant entitles to subscription and the subscription price per share have changed as follows. After the recalculation, one (1) warrant of series TO 2 will be entitled to subscription of 1.09 shares at a subscription price of SEK 0.38 per share, in accordance with the previously communicated warrant terms and conditions.

Nevisense (EIS) is included in the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for melanoma. The guidelines refer to EIS as a diagnostic support technology to aid in the detection of melanoma.

SciBase received approval from the FDA for its supplement to extend the labelling to include other healthcare professionals and not only dermatologists to perform the Nevisense procedure. Previously, the labelling only specified dermatologists as users but now it also includes healthcare professionals such as physician assistants and medical assistants working at dermatology clinics. A dermatologist still needs to initiate the test, but the actual measurement can now be performed by other healthcare professionals. This means that Nevisense now much easier can be integrated into a clinic’s workflow thus potentially expanding SciBase customer utilization and easier access for patients.

Significant events after the period

SciBase announced that a significant milestone was passed with over **400,000 Nevisense tests** sold worldwide.

The notice to attend the AGM 2026 was published.

The annual report for 2025 was published.

Consolidated summary Income Statement

SEK 000'	Jan 1 - Mar 31		Apr 1, 2025 -	
	2026	2025*	Mar 31, 2026 Rolling-12	Jan 1 - Dec 31 2025
Net sales	14 278	8 856	45 883	40 461
Cost of goods sold	-7 253	-2 614	-17 996	-13 357
Gross Profit/Loss	7 025	6 242	27 887	27 104
Sales and marketing expenses	-20 817	-16 101	-79 071	-74 355
Administration expenses	-4 105	-3 459	-14 724	-14 078
Development expenses	-6 280	-5 850	-24 282	-23 852
Other operating income	0	0	6	6
Other operating expenses	-275	-410	-1 105	-1 240
Operating Income	-24 453	-19 578	-91 288	-86 414
Financial income	252	-1 058	1 614	304
Financial expenses	-290	-46	-1 197	-953
Profit/Loss before taxes	-24 490	-20 682	-90 871	-87 063
Income tax	0	0	0	0
Profit/Loss for the period	-24 490	-20 682	-90 871	-87 063
Net Profit/Loss attributable to:				
Parent company shareholders	-24 490	-20 682	-90 871	-87 063
Earnings per share based on Net Profit/loss attributable to parent company shareholders (in SEK/share)				
Profit/loss per share (before and after dilution)**	-0,03	-0,07	-0,19	-0,24
Average number of shares outstanding	819 748	298 710	490 616	360 357

*See Note 1 Accounting Principles regarding restatements

**Profit/loss per share after dilution is not reported, since this would imply improved earnings per share

Consolidated summary statement of comprehensive income

SEK 000'	Jan 1 - Mar 31		Apr 1, 2025 -	
	2026	2025*	Mar 31, 2026 Rolling-12	Jan 1 - Dec 31 2025
Profit/loss for the period	-24 490	-20 682	-90 871	-87 063
<i>Other comprehensive income for the period:</i>				
<i>Items that have or may be reclassified to profit or loss:</i>				
Translation differences on foreign operations	-325	-248	364	442
Sum other comprehensive income	-325	-248	364	442
Total comprehensive income for the period	-24 816	-20 929	-90 507	-86 621
Total comprehensive income attributable to:				
Parent company shareholders	-24 816	-20 929	-90 507	-86 621



Consolidated summary statement of financial position

SEK 000'	March 31		Dec 31
	2026	2025	2025
ASSETS			
<i>Fixed Assets</i>			
Tangible fixed assets	971	1 284	1 095
Right of use assets	4 074	3 573	3 138
Financial fixed assets	0	0	0
Total Tangible Assets	5 045	4 858	4 233
<i>Current Assets</i>			
Inventory	9 732	7 813	9 268
Current tax receivable	843	784	660
Receivables	13 351	9 232	11 854
Other current receivables	3 468	3 070	3 549
Cash equivalents	71 255	34 295	22 604
Total Current Assets	98 650	55 194	47 936
Total Assets	103 694	60 052	52 169
Shareholders' Equity and Liabilities			
Shareholders' equity attributable to parent company shareholders	58 114	43 003	6 656
<i>Longterm Liabilities</i>			
Long-term lease liabilities IFRS-16	1 789	1 023	540
Loan	20 000	0	20 000
Total Longterm Liabilities	21 789	1 023	20 540
<i>Current Liabilities</i>			
Accounts payable	7 684	3 721	5 544
Short-term lease liabilities (IFRS-16)	2 138	2 480	2 489
Other current liabilities	13 970	9 824	16 940
Total Current Liabilities	23 792	16 025	24 973
Total Liabilities	45 580	17 048	45 513
Total shareholders' equity and liabilities	103 694	60 052	52 169



Consolidated change in shareholders' equity

SEK 000'	Share Capital	Other Capital Contributions	Accumulated Loss	Total shareholders' Equity attributable to parent company shareholders
Opening balance Jan 1, 2025	10 977	760 102	-734 429	36 651
Profit/loss for the period			-20 682	-20 682
Other comprehensive income		0	-248	-248
Total comprehensive income	0	0	-20 930	-20 930
<i>Transactions with shareholders:</i>				
New share issue	5 938	47 503		53 441
Issue expenses		-3 654		-3 654
At the end of 2024 ongoing share issue		-22 504	0	-22 504
Total transactions with shareholders	5 938	21 345	0	27 283
Closing balance Mar 31, 2025	16 915	781 447	-755 359	43 003
Opening balance Jan 1, 2026	20 709	806 996	-821 049	6 656
Profit/loss for the period			-24 490	-24 490
Other comprehensive income		-185	-140	-325
Total comprehensive income	0	-185	-24 631	-24 816
<i>Transactions with shareholders:</i>				
New share issue	30 417	49 437		79 854
Issue expenses		-3 581		-3 581
Total transactions with shareholders	30 417	45 856	0	76 274
Closing balance Mar 31, 2026	51 127	852 668	-845 680	58 114

Consolidated summary statement of cash flows

SEK 000'	Apr 1, 2025 -			
	Jan 1 - Mar 31 2026	Mar 31, 2026	Jan 1 - Dec 31 2025	Rolling-12
Cashflow from operating activities before change in working capital	-23 329	-20 411	-86 421	-83 503
<i>Cashflows from changes in working capital</i>				
Change in Inventory	-464	508	-1 920	-948
Change in Receivables	-1 598	1 388	-4 576	-1 590
Change in Liabilities	-1 182	-7 486	7 766	1 462
<i>Total change in working capital</i>	-3 244	-5 590	1 271	-1 076
Cashflow from operating activities	-26 573	-26 001	-85 150	-84 579
<i>Investment activities</i>				
Acquisitions of Fixed Assets	0	0	-228	-228
Cashflow from investment activities	0	0	-228	-228
<i>Financing activities</i>				
New share issues	79 854	53 441	110 209	83 796
Expenses related to new share issues	-3 581	-3 654	-4 592	-4 665
Loan	0	-	20 000	20 000
Repayment of lease liabilities	-712	-676	-2 876	-2 839
Cashflow from financing activities	75 561	49 111	122 742	96 292
Cashflow for the period	48 988	23 110	37 364	11 485
Cash equivalents at start of the year	22 603	11 245	34 295	11 245
Exchange rate differences in cash equivalents	-336	-60	-403	-127
Cash equivalents at end of the period	71 255	34 295	71 255	22 604



Income statement, Parent Company

SEK 000'	Apr 1, 2025 -			
	Jan 1 - Mar 31	Mar 31, 2026	Jan 1 - Dec 31	
	2026	2025	Rolling-12	2025
Net Sales	1 186	1 186	4 744	4 744
Gross profit	1 186	1 186	4 744	4 744
Administration expenses	-3 802	-3 551	-14 321	-14 071
Other Income	0	0	0	0
Other expenses	-4	1	-4	1
Operating Profit/loss	-2 620	-2 365	-9 581	-9 326
<i>Earnings from financial items:</i>				
Profit/Loss from shares in group companies	-11 432	-15 603	-151 906	-156 076
Financial income	2	122	158	277
Financial expenses	-210	0	-322	-112
Profit/loss after financial items	-14 258	-17 845	-161 651	-165 238
Taxes	-	-	-	-
Profit/loss for the period	-14 258	-17 845	-161 651	-165 238

Statement of other comprehensive income, Parent Company

SEK 000'	Apr 1, 2025 -			
	Jan 1 - Mar 31	Mar 31, 2026	Jan 1 - Dec 31	
	2026	2025	Rolling-12	2025
Profit/loss for the period	-14 258	-17 845	-161 651	-165 238
<i>Other comprehensive income</i>	-	-	-	-
Total other comprehensive income	-	-	-	-
Total comprehensive income	-14 258	-17 845	-161 651	-165 238



Summary Balance Sheet, Parent Company

SEK 000'	Mar 31		Dec 31
	2026	2025	2025
ASSETS			
<i>Fixed Assets</i>			
Shares in Group Companies	137 647	137 647	137 647
Total Fixed Assets	137 647	137 647	137 647
<i>Current Assets</i>			
Current receivables and prepaids	19 824	83 069	6 059
Cash equivalents	57 143	28 565	9 300
Total Current Assets	76 967	111 634	15 359
TOTAL ASSETS	214 614	249 280	153 005
SHAREHOLDERS' EQUITY AND LIABILITIES			
<i>Shareholder's equity</i>			
Restricted equity			
Share capital	51 127	16 915	20 709
Non-restricted equity			
Other capital contributions	852 550	781 330	806 879
Retained earnings	-698 699	-533 462	-533 462
Profit/Loss for the period	-14 258	-17 845	-165 238
Shareholders equity	190 719	246 937	128 889
<i>Long-term liabilities</i>			
Loan	20 000	-	20 000
<i>Current Liabilities</i>			
Current liabilities	3 894	2 343	4 116
Total liabilities	23 894	2 343	24 116
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	214 614	249 280	153 005



Notes

Note 1 Accounting principles

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report with the exception of what is stated below. Significant accounting and valuation principles are detailed on pages 54–60 of the consolidated annual report for 2025. The Group's lending to the wholly owned American subsidiary SciBase Inc. constitutes part of the net investment in the foreign operation as of 2025 in accordance with IAS 21 p. 15. The background is that the receivable in practice constitutes an extension of the parent company's net investment in the subsidiary, as settlement of the receivable is neither planned nor probable in the foreseeable future. Exchange rate differences that arise when translating the receivable to the closing rate are therefore reported in other comprehensive income and accumulated in the translation reserve in equity, instead of being reported as financial income/expense in the income statement. The change has been applied retroactively and all presented comparative figures have been restated in accordance with IAS 8.

Note 2 Fair value of financial instruments

Current receivables and liabilities

For current receivables and liabilities, such as accounts receivable and accounts payable with a maturity of less than six months, the carrying amount is considered to reflect fair value.

Note 3 Contingent Liabilities

The Parent Company issued a capital adequacy guarantee to its wholly owned subsidiary SciBase AB to secure that the equity at minimum corresponds to the share capital that is valid until the end of 2024. A corresponding agreement was in-place in 2023, 2022, 2021, 2020, 2019, 2018, 2017, 2016, 2015 and 2014 as well.

Note 4 Seasonal effects

To a certain extent, SciBase's sales and operating profit are expected to be dependent on seasonal variation that the company cannot influence. In the third quarter, due to the vacation period, the number of tests performed is expected to decrease and consequently the company's sales are also expected to dip.

Note 5 Information regarding operating segments

The Group has today two operating segments, skin cancer and skin barrier assessment. Follow-ups are in addition done on the geographical areas, Europe, US/North America and Asia/Oceania.

First quarter

Skin cancer

Europe

Net sales during the period amounted to TSEK 5,933 [5,902] of which Germany accounted for 98 [99]%. In the period the focus for the sales and marketing effort has continued to be Germany with the Company's own sales organization and to some extent geographic expansion. Gross profit amounted to a profit of TSEK 3,165 [3,909].

Other geographical areas

Net sales during the period amounted to TSEK 4,873 [2,727]. The sales consisted mainly of electrode sales to dermatology practices in the US. Gross profit amounted to TSEK 3,737 [2,194].

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

Skin barrier assessment

Europe

Net sales during the period amounted to TSEK 48 [228]. Gross profit amounted to a profit of TSEK 7 [139]. The sales were to researchers within the skin barrier field.

Other geographical areas

Net sales during the period amounted to TSEK 3,425 [0]. Gross profit amounted to TSEK 116 [0]. The sale primarily relates to continued deliveries of product to Castle Biosciences (at a very low margin) for a clinical study and sales to researchers within the field of skin barrier function.

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

Note 6 Incentive program

The Group has one incentive program connected to warrants specifically for employees in the US. The Board considers it important and positive if the employees' ownership in the company increases. The Board has evaluated different incentive programs that could include all employees and following this decided to implement a normal bonus program. The goals are set by the board and normally consist of turnover goals and other strategic goals. After the end of the year, it is then assessed how well the goals have been met. However, the purpose of the program is to increase the employees' ownership in the company. The board sees increased ownership by the employees as positive as it increases the employees' incentive for the company to succeed through, for example, increased sales and thereby creating increased shareholder value. Thus, if the employee undertakes to buy shares over the market and enters into a lockup agreement (12-months), the bonus is increased by 4 times the cash bonus. The program has a maximum ceiling (including social security fees etc of SEK 3 million). For 2025 the total cost for the program was

approximately MSEK 2.8 (1.6), The outcome of the program is dependent upon reaching the set targets.

Operating segments

SEK 000'	Jan 1 - Mar 31, 2026			Jan 1 - Mar 31, 2025		
	Europe	Rest of the World	Total	Europe	Rest of the World	Total
Skincancer - Net sales	5 933	4 873	10 806	5 902	2 727	8 628
The skin barrier function - Net Sales	48	3 425	3 472	228	0	228
Net sales from external customers	5 980	8 298	14 278	6 129	2 727	8 856
Cost of goods - Skincancer	-2 767	-1 136	-3 903	-1 992	-534	-2 525
Cost of goods - Barrier function	-41	-3 309	-3 350	-89	0	-89
Cost of goods - total	-2 808	-4 445	-7 253	-2 080	-534	-2 614
Gross Profit - Skincancer	3 165	3 737	6 903	3 909	2 194	6 103
Gross Profit - Barrier function	7	116	123	139	0	139
Gross Profit - total	3 172	3 853	7 025	4 049	2 193	6 242
Operating expenses			-31 478			-25 820
Operating profit/Loss			-24 453			-19 578
Financial Income			252			-1 058
Financial Expenses			-290			-46
Group earnings - before tax			-24 490			-20 682

Net sales per category and segment

Amounts in KSEK	Jan 1 - Mar 31 2026		Jan 1 - Mar 31 2025		Rolling-12		Full Year 2025	
	Europe	Rest of the World	Europe	Rest of the World	Europe	Rest of the World	Europe	Rest of the World
<i>Skin cancer</i>								
Electrodes	5 395	4 096	5 461	2 357	24 552	13 067	24 618	11 328
Instruments	538	777	441	370	766	2 175	669	1 768
Total Skin Cancer	5 933	4 873	5 902	2 727	25 318	15 242	25 287	13 096
<i>Skin barrier function</i>								
Electrodes	24	1 132	146	0	310	1 859	433	727
Instruments	24	2 293	82	0	91	3 063	149	769
Total skin barrier function	48	3 425	228	0	402	4 922	582	1 497
<i>Total</i>								
Electrodes	5 419	5 228	5 607	2 357	24 863	14 926	25 051	12 055
Instruments	562	3 070	523	370	857	5 237	818	2 537
Total	5 980	8 298	6 129	2 727	25 720	20 164	25 869	14 593

Signatures

The Board of Directors and the President provide their assurance that this interim report provides an accurate view of the operations, position and earnings of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group.

[SciBase Holding AB]
Stockholm, May 7, 2026

Jesper Høiland
Chairman of the Board

Diana Ferro
Board member

Robert Molander
Board member

Anna Eriksrud
Board member

Pia Renaudin
CEO

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on May 7, 2026.

This year-end report has not been subject to review by the Company's auditors

This report, together with previously published interim reports, can be found in its entirety on the company's website: <http://investors.scibase.se/en/reports-and-presentations>

Contact person:
Michael Colérus, CFO, +46 70 341 34 72

Quarterly overview

THE GROUP	2026		2025		2024				
	Q1	Q4	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Net sales, SEK ths	14 278	12 475	10 339	8 791	8 856	8 598	8 408	6 641	6 057
Gross margin, %	49,2%	63,0%	69,5%	66,2%	70,5%	68,5%	75,7%	69,1%	69,9%
Equity/Asset ratio, %	56,0%	12,8%	62,0%	61,1%	71,6%	59,4%	67,6%	71,8%	58,2%
Net indebtness, multiple	0,78	6,84	0,61	0,64	0,40	0,68	0,48	0,39	0,72
Cash equivalents, SEK ths	71 255	22 604	24 757	23 958	34 295	11 245	24 714	43 271	20 272
Cashflow from operating activities, SEK ths	-26 573	-20 824	-17 287	-20 466	-26 001	-12 548	-16 475	-15 179	-13 182
Earnings per share (before and after dilution), SEK	-0,03	-0,06	-0,05	-0,07	-0,07	-0,10	-0,08	-0,08	-0,09
Shareholder's equity per share, SEK	0,07	0,02	0,09	0,10	0,14	0,17	0,17	0,28	0,25
Average number of shares, 000'	819 748	414 183	390 239	338 296	298 710	219 538	219 538	186 303	119 831
Number of shares at closing of period, 000'	1 022 530	414 183	414 183	366 296	338 296	219 538	219 538	219 538	119 831
Share price at end of period, SEK	0,35	0,29	0,38	0,38	0,42	0,41	0,48	0,51	0,39
Number of sold electrodes, pieces	30 460	28 634	21 278	18 398	17 870	17 132	17 210	14 016	13 724
Average number of employees	46	43	34	35	35	30	29	27	26

Definitions

Financial key ratios

- **TSEK:** SEK 000'
- **Gross margin, %:** Gross profit divided by net sales.
- **Operating profit:** Operating income less operating expenses.
- **Operating margin, %:** Operating profit divided by income.
- **Equity/assets ratio:** Equity at the end of the period divided by total assets at the end of the period.
- **Debt/equity ratio:** Total liabilities in relation to equity.
- **Earnings per share for the period before dilution:** Profit for the period divided by average number of shares before dilution.
- **Earnings per share for the period after dilution:** Profit for the period divided by average number of shares after dilution. Earnings per share after dilution is the same as before dilution because potential ordinary shares do not cause dilution.
- **Shareholders' equity per share:** Equity divided by average number of shares.
- **Dividend per Share:** Dividend for the period divided by average number of shares after dilution.
- **Number of shares before dilution at the end of the period:** Number of shares in issue before dilution at the end of the period.
- **Average number of shares before dilution:** Average number of shares during the period before dilution.
- **Average number of shares after dilution:** Average number of shares in issue after dilution is the same as before dilution because potential ordinary shares do not cause dilution.
- **Number of employees (average):** Weighted average number of employees in the relevant period.
- **IFRS:** International Financial Reporting Standards

Industry specific glossary

- **CE labeling:** A mandatory conformity marking to show that products sold within the European Economic Area (EEA) since 2008 fulfills the requirements of the acquis. CE labeling is also included on products sold outside the EEA but that are produced in the EEA or intended for sale there.
- **Dermatoscopy or Dermoscopy:** Examination of skin lesions with a dermatoscope, a strong magnifying glass with a built-in light source.
- **Electrical Impedance Spectroscopy (EIS):** A measure of the overall impedance occurring in tissue when alternating current is applied at a series of alternating frequencies. This is measured by transmitting an imperceptible alternating current between the bands on the electrode, which is mounted on the tip of the probe and measures the current.
- **FDA:** The US Food and Drug Administration is the US authority controlling all aspects of the development, manufacture and commercialization of pharmaceutical products and medical devices in the United States.
- **Melanoma:** The most dangerous form of skin cancer, consisting of cancer in pigment-producing melanocytes.
- **Unnecessary excision:** The removal of benign skin lesions/birthmarks.
- **Nevi:** Lesions.
- **PMA:** Pre-Market Approval, a form of approval from the US FDA required for all new Class III devices.



Alternative performance measures (APM)

This section contains a reconciliation of certain alternate performance measures (APM) against the most reconcilable items in the financial statements. The reporting of APMs has limitations as analytical tools and should not be viewed without context or as compensation for financial measures prepared in accordance with IFRS. APMs are reported to improve investors' evaluation of ongoing operating profit, as a means of predicting future periods, and to simplify a meaningful comparison of results between periods. Management uses these APMs to evaluate, among other things, ongoing operations compared with previous results, for internal planning and forecasting, as well as for calculation of certain performance-related compensation. The APMs reported in this interim report may differ from measures with similar terms used by other companies.

APM for the period:

Gross Margin (%)

	2026	2025
Gross Profit	7 025	6 242
Net Sales	14 278	8 856
Gross Margin (%)	49,2%	70,5%

Definition:

Gross Profit / Loss divided with Net Sales.

Cause of use:

The gross margin shows the difference between net sales and the cost of goods sold in % of net sales. The gross margin is affected by several factors such as productmix, price trends, exchange rate fluctuation, efficiency in manufacturing processes etc. This is an important measurement as it provides a better understanding of the Company's progress.

Shareholder Equity ratio (%)

	2026	2025
Total Shareholders' Equity	58 114	43 003
Total Assets	103 694	60 052
Shareholders' Equity ratio (%)	56,0%	71,6%

Definition:

Total Shareholders' Equity at the end of the period divided with Total Assets at the end of the year.

Cause of use:

Shareholders equity ratio shows the Group's financial sustainability and the portion that is financed by equity.

Debt ratio (times)

	2026	2025
Total Liabilities	45 580	17 048
Total Shareholders' Equity	58 114	43 003
Debt ratio (times)	0,78	0,40

Definition:

Total debt in relation to Total Shareholders' Equity.

Cause of use:

The debt ratio indicates how much debt the Company is using to finance its assets relative to the value of shareholders' equity. It is closely connected to the Shareholder's equity ratio.

Earnings per share, after dilution (sek)

	2026	2025
Profit/Loss for the period	-24 490	-20 682
Average number of shares (thousand)	819 748	298 710
Earnings per share (sek)	-0,03	-0,07

Definition:

Is the portion of a company's profit allocated to each outstanding share of common stock after dilution. The result per share after the dilution is no different than before the dilution due to that potential common stock do not give rise to a dilution effect.

Cause of use:

This shows the value per share.

Shareholders' equity per share (sek)

	2026	2025
Shareholders' Equity	58 114	43 003
Average number of shares (thousand)	819 748	298 710
Shareholders' equity per share	0,07	0,14

Definition:

Shareholders' equity divided with the average number of shares after dilution

Cause of use:

The shareholders' equity per share provides a measure of the net worth per share and can be set in relation to the actual stock price

Average number of shares (thousand)

	2026	2025
Opening balance - Jan 1	414 183	219 538
Closing balance - December 31	1 022 530	338 296
Average number of shares (thousand)	819 748	298 710

Definition:

The average number of issued shares.

Cause of use:

The average number of shares gives a more accurate picture of the result and shareholders' equity due to the fact that the number of shares can change.



Pia Renaudin
CEO
+46 73 206 98 02
pia.renaudin@scibase.com

Read more about the company and its operations
at our website >> www.scibase.com



Michael Colérus
CFO
+46 70 341 34 72
michael.colerus@scibase.com

Future reporting dates

AGM 2026 May 19, 2026

Interim report Q2, August 19, 2026

Interim report Q3, November 12, 2026

Year-end report 2026, February 2027



SciBase Holding AB, Landsvägen 39, Box 3337, SE-103 67 Stockholm. Tel: +46 8 410 620 00 Fax: +46 8 615 22 24
Org nr 556773-4768 | info@scibase.com